Involve Medical Affairs in insight management, early phases of clinical trials, etc.

It’s Never Too Soon: How and When to Engage Medical Affairs

Engagement with Medical Affairs is critical at every juncture in the drug development process, with Medical Affairs acting as a key liaison between internal stakeholders, a new generation of physicians, and patient advocates...
Read More

Top Stories

Involve Medical Affairs in insight management, early phases of clinical trials, etc.

It’s Never Too Soon: How and When to

Engagement with Medical Affairs is critical at every...
Health Literacy Month

Celebrating Health Literacy Month 2024:

October is Health Literacy Month, a reminder of the...
world patient safety day

Celebrating World Patient Safety Day 2024:

On World Patient Safety Day 2024, we focus on the critical...
Stakeholder perspectives on digital scientific content

Digital Scientific Content: Stakeholder Perspectives

What do the different relevant stakeholder groups truly expect from pharma-generated scientific content?...
A summarized report of the Virtual MedTech

A Summarized Report of the Virtual MedTech EU MDR Exchange Conference

Session summaries from EUMDR exchange conference 2021...
How Can Preprints Drive Trust In Science?

How Can Preprints Drive Trust in Science?

By tagging preprints with various indicators, badges may represent quality, rigor, and scope. In doing...
equity diversity and inclusion

How to Incorporate and Drive Equity, Diversity, and Inclusion in Medical Communications and Publications

A roadmap on how to drive advocacy for EDI in medical communications and publications and...
reimagining scientific communications

Scientific Communication Strategies for Digital Transformation

Read how digital transformation strategies can help to rethink workflows for future readiness and scale-up...
Medical Affairs - 2025

Vision 2025: Decoding the Medical Affairs Landscape

Medical Affairs is a critical strategic pillars of pharma. Read how Medical Affairs will evolve...

Learn more ABOUT our company.